To print: Select File and then Print from your browser's menu --------------------------------------------------------------------------------------- Title: DG DISPATCH - NCI-EORTC-AACR: Endostatin Shows Promising Anticancer Activity With Low-Toxicity Profile URL: http://www.pslgroup.com/dg/1EA402.htm Doctor's Guide November 10, 2000
By Ed Susman Special to DG News
AMSTERDAM, THE NETHERLANDS -- November 10, 2000 -- In the first three clinical trials of the anti-angiogenesis drug, endostatin, researchers said they found virtually no toxicity caused by the genetically-engineered product -- and they were encouraged by evidence in a few patients that endostatin appears to have biological activity against cancer.
"If you are going to have a drug that has to be taken for long periods of time-and that is probably going to be the case with endostatin-it cannot have serious side effects," said James Thomas, MD, assistant professor of medicine at the University of Wisconsin Medical School, in Madison, Wisconsin.
No significant side effects were seen in any of the 61 patients in the three studies presented at the 11th National Cancer Institute-European Organization for Research and Treatment of Cancer-American Association for Cancer Research symposium (NCI-EORTC-AACR).
The dose escalating studies did not find adverse side effects at doses as high as 300 mg, Dr. Thomas explained. Patients were begun on doses as low as 15 mg.
James Abbruzzese, MD, professor of medicine at the University of Texas M.D. Anderson Cancer Center, in Dallas, Texas, said his research group will begin administering doses of 600 mg in another half dozen patients in the continuing Phase I study. --------------------------------------------------------------------------------------------- Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content. --------------------------------------------------------------------------------------------- This news story was printed from *Doctor's Guide to the Internet* located at http://www.docguide.com --------------------------------------------------------------------------------------- Return to News Story Page This site is maintained by webmaster@pslgroup.com Please contact us with any comments, problems or bugs. All contents Copyright (c) 1998 P\S\L Consulting Group Inc. All rights reserved.